Marshall Wace North America’s Vir Biotechnology VIR Stock Holding History

Marshall Wace North America’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-106,594	Closed	-$5.46M	–	1798
2021 Q1	$5.46M	Buy	+106,594	New	+$5.74M	0.02%	539
2020 Q1	–	Sell	-74,898	Closed	-$941K	–	1622
2019 Q4	$941K	Buy	+74,898	New	+$1M	﹤0.01%	723

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Marshall Wace North America's VIR Position: Q2 2021 in Review

Marshall Wace North America sold out of Vir Biotechnology (VIR) in Q2 2021, closing a stake of 106,594 shares — an estimated $5.46M sold.

Marshall Wace North America first reported a position in VIR in Q4 2019 and held it in 2 quarters. The position peaked at $5.46M in Q1 2021. 166 funds tracked by Wall St. Rank hold VIR as of Q2 2021.

Marshall Wace North America reported no remaining Vir Biotechnology position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 106,594 Vir Biotechnology shares in Q2 2021, an estimated $5.46M.
Marshall Wace North America first reported a position in Vir Biotechnology in Q4 2019 and held it in 2 quarters.
Marshall Wace North America's Vir Biotechnology position peaked at $5.46M in Q1 2021.
166 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.